Olatec Therapeutics, Inc. | ClinicalTrials HQ

4 results · Page 1 of 1

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
A Trial to Test the Use of Dapansutrile, an Anti-inflammatory Medication, in People With Parkinson's Disease	Inflammation, Nerve Degeneration, Neuroinflammatory Diseases, Parkinson disease, Pathologic Processes, Pathological Conditions, Signs and Symptoms, basal ganglia disorder, brain disorder, central nervous system disorder, movement disorder, nervous system disorder, neurodegenerative disease, parkinsonian disorder, synucleinopathy	Recruiting	Phase 2	2026-06-16		NCT07157735
Study of Dapansutrile Tablets in Subjects With an Acute Gout Flare	Arthralgia, Arthritis, Gouty, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Crystal Arthropathies, Hyperuricemia, Inflammation, Neurologic Manifestations, Nutritional and Metabolic Diseases, Pain, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, arthritic joint disease, arthropathy, gout, hereditary disease, inborn disorder of purine or pyrimidine metabolism, inborn errors of metabolism, metabolic disease, musculoskeletal system disorder, rheumatic disorder	Recruiting	Phase 2 / Phase 3	2026-03-11		NCT05658575
Dapansutrile in Diabetes and Diabetes-Related Complications - Dapan-Dia	Nutritional and Metabolic Diseases, diabetes mellitus, endocrine system disorder, glucose metabolism disease, metabolic disease, type 2 diabetes mellitus	Recruiting	Phase 2	2026-02-25		NCT06047262
A Study of Dapansutrile Plus Pembrolizumab in Patients With PD-1 Refractory Advanced Melanoma	Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Skin and Connective Tissue Diseases, melanocytic neoplasm, melanoma, neoplasm, neuroendocrine neoplasm, primitive neuroectodermal tumor, skin disorder, skin neoplasm	Active, not recruiting	Phase 1 / Phase 2	2026-02-20		NCT04971499